Lifeline Biotechnologies (LLBO) currently reports a EBIT of $-34K as of June 2026. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Lifeline Biotechnologies's EBIT history and peer comparisons.

Lifeline Biotechnologies's EBIT of $-34K is lower than the Healthcare sector average of $22B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Lifeline Biotechnologies reported $-34K in EBIT as of June 2026. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-34K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Lifeline Biotechnologies, and consider following LLBO for alerts when major investors trade the stock.

Lifeline Biotechnologies is classified in the Healthcare sector. On EBIT, it currently shows $-34K versus a sector average near $22B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LLBO with unrelated industries.